Due to the aforementioned data and the relationship between endothelial dysfunction and T2D-related HF, we hypothesized that VEGF, VCAM-1, and ICAM-1 could be the best markers for monitoring the severity of acute heart failure (congestion) and the impact of administered therapy on this congestion, and in the changes in the plasma levels of these markers would be more highly expressed (VEGF is expected to be lower, whereas VCAM-1 and ICAM-1 are expected to be higher) in patients with T2D. The gene discussed is ICAM1; the disease is endothelial dysfunction.